Findings

What do systematic reviews say?

4 questions · 6 findings · 1 reviews · Vascular

No studies found 3 · 50%GRADE not reported 1 · 16.7%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 2 · 33.3%

Total VTE · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Total VTE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin leads to lower any VTE compared with no thromboprophylaxis (high certainty).

1 finding from 1 review

Total VTE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin showed no clear difference in any VTE compared with with active control (1); GRADE not reported.

3 findings from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 4.81 [0.24, 95.58]
Studies not reported
GRADE not reported
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Total VTE · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin leads to lower any VTE compared with placebo (high certainty).

1 finding from 1 review